CN111919934A - Safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular and preparation method thereof - Google Patents

Safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular and preparation method thereof Download PDF

Info

Publication number
CN111919934A
CN111919934A CN202010979113.6A CN202010979113A CN111919934A CN 111919934 A CN111919934 A CN 111919934A CN 202010979113 A CN202010979113 A CN 202010979113A CN 111919934 A CN111919934 A CN 111919934A
Authority
CN
China
Prior art keywords
tea
parts
safflower
high blood
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010979113.6A
Other languages
Chinese (zh)
Inventor
傅松涛
焦宝元
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202010979113.6A priority Critical patent/CN111919934A/en
Publication of CN111919934A publication Critical patent/CN111919934A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F3/00—Tea; Tea substitutes; Preparations thereof
    • A23F3/06—Treating tea before extraction; Preparations produced thereby
    • A23F3/14—Tea preparations, e.g. using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/286—Carthamus (distaff thistle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/287—Chrysanthemum, e.g. daisy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482—Cassia, e.g. golden shower tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/489—Sophora, e.g. necklacepod or mamani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/535—Perilla (beefsteak plant)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A61K36/605—Morus (mulberry)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/62—Nymphaeaceae (Water-lily family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH

Abstract

The invention discloses a safflower perilla heart tea for reducing high blood pressure, high blood sugar and protecting cardiovascular, which comprises the following components in parts by weight: 15-1000 parts of tea, 5-300 parts of safflower, 5-150 parts of perillaseed, 5-150 parts of lotus plumule, 5-300 parts of cassia seed, 2-300 parts of medlar, 2-300 parts of chrysanthemum, 2-150 parts of sophora flower bud, 5-300 parts of hawthorn, 5-300 parts of mulberry leaf and 1-50 parts of momordica grosvenori. The invention also discloses a preparation method of the safflower perilla heart tea for reducing high blood pressure, high blood sugar and protecting the cardiovascular system. The invention adopts the mode of adding seasoning tea, so that patients can take tea for health care every day, the tea is convenient, the side effect of medicines is avoided, and the cost is low.

Description

Safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular and preparation method thereof
Technical Field
The invention relates to a safflower perilla heart tea for reducing high blood pressure, high blood sugar and high blood fat and protecting cardiovascular and a preparation method thereof, belonging to the technical field of processing of seasoning tea.
Background
Hypertension, hyperglycemia and hypertriglyceridemia are collectively called hypertension, hyperglycemia and hyperlipidemia, which are the main culprits of cardiovascular and cerebrovascular diseases and seriously harm human health.
Hypertension refers to the condition of higher than normal blood pressure in the circulatory system, usually refers to the increase of systemic arterial blood pressure, and is a common clinical syndrome. Normally, the blood pressure is lower than 140/90 mmhg, and higher than 160/95 mmhg.
Hyperlipidemia refers to the condition of high blood cholesterol or triglyceride or low high-density lipoprotein cholesterol, and is called as dyslipidemia in modern medicine. It is a main factor causing atherosclerosis and is a risk factor for occurrence and development of cardiovascular and cerebrovascular diseases. It is latent in onset and mostly has no clinical symptoms.
Hyperglycemia is the condition that the glucose content in the blood of a body is higher than a normal value and is mostly caused by pathological changes of islet cells existing in the body, and the key of pathological changes is blood sugar metabolic disorder.
The clinical manifestations of hyperglycemia can have dominant symptoms, such as thirst, much drinking water, much urine and emaciation; or may be implicit with no apparent subjective discomfort. The early stage of the hypertension patient can show symptoms of headache, dizziness, tinnitus, palpitation, dim eyesight, inattention, hypomnesis, numbness of hands and feet, fatigue, weakness, easy dysphoria and the like, and the degree of the symptoms is inconsistent with the degree of the increase of the blood pressure; the later stage blood pressure is always kept at a high level, and brain, heart, kidney and other organs are damaged and even fail by accelerating atherosclerotic lesions. Diabetes is a chronic and lifelong disease, is a common disease seriously harming human health, and causes abnormal metabolism of nutrients such as carbohydrate, fat, protein and the like in vivo due to relative or absolute deficiency of insulin. The disease can cause various complications, and can cause systemic diseases when serious, which causes people to be disabled, blindness and even death. The long-term hyperlipidemia easily causes atheromatous plaque to deposit on the blood vessel wall, gradually forms atherosclerosis, leads to the stenosis of the lumen of the blood vessel, and leads to the attenuation and even the interruption of the blood flow. In addition, hyperlipidemia and extensive atherosclerosis can cause hypertension, aggravate fatty liver, induce gallstone and pancreatitis, aggravate cerebral apoplexy and coronary heart disease.
Hypertension, hyperglycemia and hyperlipidemia can exist independently and are often mutually associated, and three types of hypertension, hyperglycemia and hyperlipidemia are integrated in the later stage. Traditional hypoglycemic drugs, antihypertensive drugs and hypolipidemic drugs are easy to resist drugs, the drug types are increased, the dosage is increased, the damage to gastrointestinal tracts and liver and kidney functions of patients after long-term administration is very large, complications are easy to cause, and the life quality of the patients is seriously affected.
According to the national supply and marketing headquarters seasoning tea industry standard GH/T1247-2019, the seasoning tea is a product which is prepared by adding a proper amount of other food raw materials and/or food additives into tea serving as a raw material and is drunk by people in a brewing (soaking or boiling) mode.
Disclosure of Invention
The purpose of the invention is as follows: the present invention is to solve the above problems of the prior art, and it is a first object of the present invention to disclose a safflower perilla heart tea for reducing high blood pressure, high blood sugar and protecting the cardiovascular system. The second purpose of the invention is to disclose a preparation method of safflower perilla heart tea for reducing high blood pressure, high blood sugar and protecting the cardiovascular system.
The technical scheme is as follows: a safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting the cardiovascular system comprises the following components in parts by weight: 15-1000 parts of tea, 5-300 parts of safflower, 5-150 parts of perillaseed, 5-150 parts of lotus plumule, 5-300 parts of cassia seed, 2-300 parts of medlar, 2-300 parts of chrysanthemum, 2-150 parts of sophora flower bud, 5-300 parts of hawthorn, 5-300 parts of mulberry leaf and 1-50 parts of momordica grosvenori.
Further, comprising: 600 parts of tea, 200 parts of safflower, 150 parts of perilla fruit, 150 parts of lotus plumule, 150 parts of cassia seed, 100 parts of medlar, 100 parts of chrysanthemum, 100 parts of sophora flower bud, 150 parts of hawthorn, 150 parts of mulberry leaf and 20 parts of momordica grosvenori.
Furthermore, the tea is any one or more of green tea, white tea, yellow tea, oolong tea, black tea and black tea.
A preparation method of safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular comprises the following steps:
(1) preparing a first filtrate:
(11) weighing the safflower, the perilla fruit, the medlar, the chrysanthemum and the sophora flower bud according to the formula ratio, selecting, screening and removing impurities, cleaning, and placing in an extraction container;
(12) and leaching for the first time:
adding 10-85% V/V ethanol aqueous solution with the volume 5-25 times that of the extraction container, leaching for 4-96 hours at the temperature of 20-75 ℃, filtering, and collecting leaching liquor;
(13) and leaching for the second time:
adding 10-85% V/V ethanol aqueous solution with the volume of 3-20 times that of the extraction container, leaching for 2-72 hours at the temperature of 20-75 ℃, filtering, and collecting leaching liquor;
(14) and leaching for the third time:
adding 10-85% V/V ethanol aqueous solution with the volume of 3-20 times that of the extraction container, leaching for 2-72 hours at the temperature of 20-75 ℃, filtering, and collecting leaching liquor;
(15) combining the leaching liquor obtained in the steps (12) to (14), naturally cooling to normal temperature, standing for 12-96 hours in an environment at 1-10 ℃, collecting supernatant, filtering by using a filter material with a pore size of 0.2-0.5 micrometer, and collecting filtrate to obtain first filtrate;
(2) preparing a second filtrate:
(21) weighing lotus plumule, cassia seed, hawthorn, mulberry leaf and momordica grosvenori according to the formula ratio, selecting, screening and cleaning impurities, and placing the mixture into an extraction container;
(22) and first decoction:
adding 8-30 times of water into the extraction container, soaking for 0.5-4.5 hours, heating to boil, decocting for 0.5-4.5 hours, filtering, and collecting decoction;
(23) and carrying out second decoction:
adding 6-25 times of water by volume into the extraction container, heating to boil, decocting for 0.5-4.5 hours, filtering, and collecting decoction;
(24) and decocting for the third time:
adding 6-25 times of water by volume into the extraction container, heating to boil, decocting for 0.5-4.5 hours, filtering, and collecting decoction;
(25) combining the decoction obtained in the steps (22) to (24), filtering the decoction by a filter screen of 20-300 meshes, centrifuging 300-1200 g to remove fine precipitates, concentrating the supernatant under reduced pressure at 55-95 ℃ and-0.05-0.1 MPa, and concentrating the concentrate into a concentrated solution with the relative density of 1.05-1.25 to obtain a second filtrate;
(3) adding 2-4 times of volume of 90% V/V ethanol aqueous solution into the second filtrate obtained in the step (2) at the temperature of 5-65 ℃, fully stirring, naturally cooling to normal temperature, standing for 12-96 hours in an environment at the temperature of 1-25 ℃, collecting supernatant, filtering the supernatant through a filter material with the filter diameter of 0.2-1.0 micron, and collecting filtrate;
(4) combining the first filtrate obtained in the step (1) and the filtrate obtained in the step (3), fully and uniformly mixing, concentrating under reduced pressure at 55-95 ℃, and-0.05-0.1 MPa, and concentrating the filtrate to the volume of a concentrated solution: the feeding amount of the raw materials is 1 (1-4), and a concentrated solution is obtained, wherein:
the volume of the concentrated solution is measured by milliliter, and the feeding amount of the raw materials is measured by gram;
(5) weighing the picked tea leaves according to the formula ratio, flatly paving the tea leaves in a baking pan with the paving thickness of 0.5-8 cm, and placing the baking pan paved with the tea leaves in a baking oven for ventilation baking at 65-120 ℃ for 0.5-4 hours;
(6) uniformly spraying the concentrated solution obtained in the step (4) on the tea leaves in the baking pan for 1-10 times, and fully stirring to enable the liquid medicine to be completely adsorbed by the tea leaves, wherein:
between two adjacent spraying, continuously baking the tea leaves for 2-6 hours at 65-120 ℃ in a ventilating way, and uniformly turning over the materials every 0.5-2 hours;
(7) and (3) after the concentrated solution obtained in the step (4) is completely and uniformly mixed with the tea leaves in the tray, continuously performing ventilation baking at 65-120 ℃, uniformly turning over the materials every 0.5-2 hours until the tea leaves are dry and slightly pungent, gripping the tea leaves, enabling the tea leaves to be elastic and conglobate, and slightly touching the tea leaves with force to disperse tea leaves particles, thus preparing the safflower Suxin tea for reducing hypertension, hyperglycemia and hyperlipidemia and protecting the cardiovascular system.
Further, the method also comprises the step (8): and (3) adding the safflower perilla heart tea prepared in the step (7) for reducing the three highs and protecting the cardiovascular system into an automatic packaging machine for packaging, and carrying out aluminum-plastic packaging to obtain 1-5000 g of independent packages, thus obtaining the safflower perilla heart tea for reducing the three highs and protecting the cardiovascular system.
Further, ethanol is recovered simultaneously during the concentration under reduced pressure in the step (4).
Further, the tea in the step (5) is prepared by compounding any one or more of green tea, white tea, yellow tea, oolong tea, black tea and black tea.
The invention discloses a compatibility principle of safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular system: tea leaves are used as a main body and a carrier, extracted components of traditional Chinese medicines which are homologous in medicine and food, such as safflower, perilla fruit, lotus plumule and the like are used as auxiliary functional components, and the tea is drunk daily to help consumers to reduce blood sugar, blood fat and blood pressure and protect heart and cerebral vessels. Wherein
Tea leaf: scientific research proves that one of the important reasons for causing the hypertension, the hyperglycemia and the hyperlipidemia is oxidative stress, and the oxidative stress can directly cause micro-vascular damage, islet beta cell apoptosis, hepatocyte steatosis and atherosclerosis. The tea polyphenol which is the main functional component of tea is a pure natural super-strong antioxidant. Research shows that the tea polyphenol has three major mechanisms of inhibiting the generation of free radicals, directly eliminating the free radicals and activating a human body to eliminate the free radical system to play an antioxidation role, and is mainly reflected in the aspects of regulating blood fat, preventing cardiovascular and cerebrovascular diseases, regulating immunologic function, delaying aging and the like. The tea drink is helpful for preventing lipid peroxidation caused by hyperlipemia oxygen free radicals, and atherosclerosis. The tea polyphenol can reduce total cholesterol and triglyceride in serum by about 19% and increase the ratio of high density lipoprotein to low density lipoprotein, and the difference between the ratio before and after experiment is 36.1%, which indicates that the tea polyphenol is helpful for preventing hyperlipidemia and atherosclerosis. The tea drinking can eliminate the excessive heavy metal ions in the body, and researches show that tea polyphenol molecules can be complexed with the heavy metal ions such as lead, tin, iron, calcium and the like to form a cyclic chelate to generate precipitation, thereby eliminating the excessive heavy metal ions in the body. The excessive iron in the body of a patient with coronary heart disease can be generated, the heart cells are damaged by free radicals caused by the iron, and if the excessive iron can be removed in time, the heart can be protected. The tea polyphenol has strong coordination ability, can coordinate with iron, and is discharged out of body in the form of complex, thereby protecting heart.
Researches show that epigallocatechin gallate (EGCG) in tea not only can obviously improve insulin activity, but also can inhibit lipase activity by activating an adenylate activated protein kinase signal, and protect islet cell signaling and lipid regulation, thereby preventing type 2 diabetes. The tea polysaccharide can eliminate excessive free radicals generated in vivo by enhancing the antioxidant function of organism, thereby protecting islet cells from free radical invasion. The tea can reduce the generation of free radicals in mice caused by type 2 diabetes by improving the activity of free radical scavenging enzyme, thus relieving the damage of islet cells to a great extent, being beneficial to reducing blood sugar and improving glycolipid metabolism. Some components in the tea pigment also have the effects of resisting oxidation and removing free radicals, so that the oxidation damage to lymphocytes is reduced after the diabetic drinks the tea, and the symptoms of the diabetic can be relieved; in addition, some scholars think that tea pigment improves systemic microcirculation and tissue metabolism level by regulating blood viscosity, thereby improving the function of insulin cells and reducing blood sugar.
Safflower: safflower is the essential drug for dredging blood vessels, relieving swelling and pain, activating blood and dissolving stasis, and stimulating the menstrual flow and relieving pain, and belongs to the drugs for breaking blood and dissolving stasis. The main chemical components are safflower quinonoid glycoside, neosafflower glycoside, safflower yellow, and safflower oil. It is one of the most widely used blood-activating and stasis-resolving medicaments. In more than ten years, the research has been greatly developed, and the safflower yellow (HSYA) can antagonize the specific binding of PAF and rabbit platelets and inhibit PAF-induced blood cell aggregation; the blood pressure of the rabbits can be effectively reduced, and the average value of the reduction of the diastolic pressure and the systolic pressure is about 10-30 mmHg. In recent years, studies on the effect of safflower extract on gene regulation have been increasing. Research shows that the safflower extract can inhibit the rapid proliferation and growth of Vascular Smooth Muscle Cells (VSMC) of rats and reduce the activity of the VSMC NF-KB, thereby treating vascular proliferative diseases such as hypertension, coronary atherosclerotic heart disease, restenosis after angioplasty and the like; the safflower is probably related to the inhibition of the expression of a pro-apoptosis agent Caspase-3 and the enhancement of the expression of an apoptosis inhibitor Bcl-2 to the cerebral ischemia-reperfusion injury, namely the safflower realizes the anti-apoptosis effect by influencing the expression of an apoptosis regulating gene and plays a role in protecting the myocardial and cerebral ischemia-reperfusion injury.
And (3) Perilla seed: modern researches show that perillaseed has the effects of regulating blood fat and resisting lipid peroxidation, and can obviously reduce the contents of TC, TG and LDL-C, MDA in serum and increase the contents of HDL-C and SOD activity in serum. Perilla seed oil is rich in unsaturated fatty acids, especially alpha-linolenic acid, and has pharmacological effects of reducing blood lipid, lowering blood pressure, resisting thrombi, resisting cancer, resisting inflammation and oxidation. Experiments show that perilla seed oil can obviously reduce the content of Total Cholesterol (TC) and Triacylglycerol (TG) in plasma of a rat with hyperlipidemia and improve the content of high-density lipoprotein cholesterol (HDL-C), and the perilla seed oil with high dose can reduce the lipid deposition in the liver of the rat with hyperlipidemia, prevent the occurrence of fatty liver and has the function of resisting hypertension.
Lotus plumule: has effects in clearing away heart-fire, tranquilizing mind, regulating functions of heart and kidney, arresting seminal emission, and stopping bleeding. Modern researches show that the main components of the lotus plumule comprise alkaloids such as liensinine, isoliensinine and neferine, and flavonoids such as luteolin glycoside, hyperoside and rutin. Has effects in lowering blood pressure, resisting arrhythmia, inhibiting platelet aggregation, resisting oxidation, scavenging active free radicals, resisting myocardial ischemia, relaxing smooth muscle, tonifying heart, resisting cancer, protecting cerebral ischemia injury, improving acute lung injury and pulmonary fibrosis, inhibiting central nervous system, and lowering blood sugar. Active components and action targets in the lotus plumule are searched through TCMSP and BATMAN-TCM databases, effective targets for treating hypertension are searched in TTD, CTD and DRUGBANK databases, and 25 components and 59 key targets are screened out from the lotus plumule, which relates to 10 main signal paths; the lotus plumule is proved to be capable of synergistically regulating and controlling blood pressure through multiple paths and improving emotional symptoms of hypertension patients. Clinical research shows that hypertension patients can reduce indexes such as carotid artery IMT, ba-PWV and the like by adding lotus plumule intervention treatment, and the lotus plumule has an anti-arteriosclerosis effect, and the effects are probably related to the influence of the lotus plumule intervention treatment on the expression level of inflammatory factors and MMP-9.
Cassia seed: sweet, bitter, salty and slightly cold in nature, has the effects of clearing heat, improving eyesight, loosening bowel to relieve constipation, and is used for treating conjunctival congestion, swelling and pain, photophobia, lacrimation, headache, vertigo, dim eyesight, habitual constipation, etc. Modern medical research considers that cassia seed has the effects of reducing blood pressure, regulating lipid, protecting liver, improving renal function and the like, and is a representative medicine for treating cardiovascular and cerebrovascular diseases, hyperlipidemia and constipation in traditional Chinese medicine. The cassia seed is ground into powder, is soaked in boiled water for meal and is taken orally, 12 cases of primary hypercholesterolemia are treated, the treatment lasts for 30 days, various indexes of blood fat are obviously reduced after the cassia seed is treated, the weight of a patient is also reduced, abdominal distension and abdominal pain disappear, and the symptoms of fatty liver are relieved. When 36 patients with coronary heart disease (9 patients with hyperlipidemia) are treated with semen Cassiae and fructus crataegi for 1 month, the blood lipid level of the patients is remarkably reduced, and the symptoms of angina pectoris are also remarkably improved. 43 cases of patients with primary hypertension are taken with cassia seed powder, and the total effective rate of lowering blood pressure is 93.02%. Experiments show that the antihypertensive effect of cassia seed is probably related to the excitation of cholinergic nerves and the excitation of peripheral M receptors. The extract of the cassia seed is drenched into Japanese big ear white rabbits of models of hyperlipemia caused by high-fat feed, and the serum cholesterol, triglyceride and low-density lipoprotein content of the model animals can be obviously reduced after the extract is continuously administrated for 14 and 28 days; the semen cassiae ethanol extract can also obviously reduce the MDA content of the serum of a model animal, improve the SOD activity and relieve the pathological damage of liver cells; when the semen cassiae extract is used for treating the fatty liver model rat, the activity of liver enzyme of the model animal can be obviously reduced, and the degree of fatty degeneration of liver cells is obviously reduced.
Medlar: sweet taste, neutral nature, entering liver, kidney and lung meridians, moistening qi and ascending and descending. Has effects in nourishing liver, improving eyesight, moistening lung, promoting salivation, invigorating qi, replenishing vital essence, nourishing liver and kidney, resisting aging, quenching thirst, warming body, and resisting tumor. Fructus Lycii is rich in carotene and vitamin A, B1、B2C, calcium, iron and other nutrients necessary for eye health care, so the eye drops are good at improving eyesight and are commonly called as 'eyesight improving eyes'. Fructus Lycii has effects of lowering blood pressure, blood lipid and blood sugar, preventing atherosclerosis, protecting liver, inhibiting fatty liver, and promoting liver cell regeneration. The medlar can effectively reduce the content of triglyceride and cholesterol in the serum of a rat with hyperlipidemia, has obvious function of reducing the blood lipid and regulates the lipid metabolism. Researches show that the functional component of the medlar, namely medlar polysaccharide 3b, has the competitive inhibition effect with glucose absorption, namely the medlar polysaccharide can delay the glucose absorption and reduce the glucose absorption by combining with glucose absorption sitesLow postprandial blood glucose. In addition, the lycium barbarum polysaccharide obviously enhances the activity of SOD (superoxide dismutase) in damaged islet cells, improves the oxidation resistance of the islet cells, lightens the damage of peroxide to the cells, and reduces the generation amount of malonaldehyde, which shows that the lycium barbarum polysaccharide has a certain protection effect on the islet cells. The lycium barbarum polysaccharide can also reduce the systolic blood pressure and the diastolic blood pressure of rats; reduce the content of malondialdehyde and endothelin in blood plasma and blood vessel, increase the release of calcitonin gene-related peptide, and prevent hypertension.
Chrysanthemum: according to the record of compendium of materia medica, chrysanthemum is indicated for wind-syndrome and dizziness, improving eyesight and dispelling wind, searching liver qi, benefiting blood and moistening face. Modern pharmacological research shows that chrysanthemum has a plurality of pharmacological effects of resisting bacteria, inflammation and oxidation, relaxing blood vessels, reducing blood fat, resisting tumors, expelling lead and the like. The flavonoids of flos Chrysanthemi have effects in enhancing resistance of capillary vessel, inhibiting capillary permeability, resisting inflammation, scavenging free radicals and oxidation, increasing coronary blood flow, resisting arrhythmia induced by aconitine and chloroform, and antagonizing Ca2+The internal flow of the medicine can improve the contractility of cardiac muscle cells, and has obvious effects of relaxing blood vessels, reducing blood pressure and blood fat. The water decoction and alcohol precipitation preparation of chrysanthemum has the function of increasing the flow of coronary artery of the heart of an experimental animal and can improve the ST-segment depression of ischemic electrocardiogram caused by electrically stimulating central nerve. Can also increase coronary flow and myocardial oxygen consumption for isolated heart of experimental coronary arteriosclerosis animal. The experimental result shows that the chrysanthemum aqueous extract can obviously inhibit lipid peroxidation caused by D-galactose, and reduce the content of Malondialdehyde (MDA) and the activity of monoamine oxidase (MAO) in blood; increasing the activity of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) in blood.
And (3) flos sophorae immaturus: the Huai Hua Xin is also called as the Huai Hua, bitter in property and slightly cold in property, and enters liver and large intestine meridians. It is called from Chinese pharmacopoeia for cooling blood to stop bleeding, clearing liver-fire and purging fire, and can be used for hematochezia, hemorrhoidal bleeding, bloody dysentery, metrorrhagia and metrostaxis, hematemesis, epistaxis, liver heat with reddish eyes, headache and vertigo. The sophora flower liquid has a transient but obvious blood pressure reducing effect and has a slight exciting effect on cardiac muscle. The main component rutin has vitamin P-like effect, can reduce abnormal permeability and fragility of capillary, and can be used for treating and preventing hypertension, cerebral hemorrhage, etc., and maintaining blood vessel resistance, etc.; the quercetin contained in the product has effects of lowering blood pressure, enhancing capillary resistance, reducing capillary fragility, dilating coronary artery, and increasing coronary blood flow. Rutin which is the main component of the sophora flower has the function of removing fat from liver infiltrated by fat, the fat removing effect is more obvious when the rutin is used together with glutathione, and the contained quercetin also has the function of reducing blood fat; the genistein contained in the composition has the effect of reducing cholesterol and triglyceride in blood of experimental hyperlipaemia rats, and has particularly obvious effect on the latter. In addition, rutin has aldose reductase inhibiting effect, and its inhibition rate at 105mol/L concentration is 95%, which is beneficial for treating diabetic cataract.
Hawthorn fruit: slightly warm in nature, sour and sweet in taste. It enters spleen, stomach and liver meridians. The hawthorn contains various active ingredients such as ursolic acid, flavonoid, saponin, sugar, organic acid, pigment and the like, has the effects of promoting digestion, removing food retention, promoting qi circulation and removing blood stasis, has the best digestion effect on human bodies, and is particularly suitable for spleen and stomach weakness, indigestion and greasy regurgitation. Haw is good at moving qi of stomach and intestine, and indicated for food retention, stomach and intestine and abdominal distention. It is used clinically in treating indigestion and postpartum abdominal pain due to blood stasis. In recent years, the hawthorn has the effects of reducing blood pressure, reducing blood fat, improving myocardial ischemia, reducing cholesterol, resisting lipid peroxidation and the like, and has good effect on treating cardiovascular and cerebrovascular diseases. The total extract or total saponin of fructus crataegi can cause blood pressure decrease of experimental mouse, rabbit and cat. The small dosage of hawthorn fluid extract, flavone or hydrolysate is injected into anesthetized cats, anesthetized rabbits or anesthetized mice, and has slow and lasting blood pressure reduction effect, and the blood pressure reduction principle is mainly based on peripheral blood vessel expansion. The hawthorn has an inhibition effect on a rate-limiting enzyme (HMG-CoA reductase) for synthesizing the cholesterol in liver cell microsomes and small intestinal mucosa, but has no obvious influence on a rate-limiting enzyme (7 alpha-hydroxylase) for decomposing the cholesterol in the liver, so that the effect of regulating lipid metabolism by the hawthorn is generated by inhibiting the synthesis of the cholesterol in the liver and increasing the level of LDLR to promote the cholesterol in plasma to be absorbed into the liver. The hawthorn and hawthorn flavone can obviously reduce the content of serum and liver Malondialdehyde (MDA), enhance the activity of erythrocyte and liver superoxide dismutase (SOD), simultaneously increase the activity of whole blood glutathione reductase (GSH-Px), and have therapeutic effect on experimental atherosclerosis. Chrysanthemum, honeysuckle and hawthorn 5: 5: the 4-formula tea drink can be used for treating patients with hyperlipidemia, hypertension and arteriosclerosis with abnormal hemorheology, and the total effective rate is 95%.
Mulberry leaf: meanwhile, the tea has the miraculous effect of reducing high blood pressure, high blood sugar and high blood sugar. Researches find that the mulberry leaves and the mulberry leaf tea rich in gamma-aminobutyric acid have definite blood pressure lowering effect and no side effect, and meanwhile, rutin, quercetin and quercitrin in the mulberry leaves can increase the contractility and output in vitro and in the frog heart and reduce the heart rate. Rutin in folium Mori can cause vasoconstriction of toad lower limbs and rabbit ear, quercetin can dilate coronary blood vessel, and improve myocardial circulation. The folium Mori contains gamma-aminobutyric acid, rutin, and quercetin, and has blood pressure lowering effect. The gamma-aminobutyric acid in mulberry leaves is a nerve transmission substance, can promote the metabolism of brain tissues and restore the function of brain cells, and simultaneously can improve the blood flow of the brain, enhance the activity of angiotensin I converting enzyme I and promote the reduction of blood pressure. Researches find that mulberry leaves generally contain rich gamma-aminobutyric acid components, and the content of the gamma-aminobutyric acid can be obviously increased by technologies such as microbial fermentation and the like. Folium Mori has effects of inhibiting fatty liver formation, reducing serum fat and inhibiting atherosclerosis formation. The active ingredients include Deoxynojirimycin (DNJ), phytosterol, flavonoids, polysaccharides, etc. The mulberry leaves contain flavonoid components for strengthening capillary vessels and reducing blood viscosity, and the mulberry leaves contain components for resisting LDL-lipoprotein oxidation in vivo, so that the mulberry leaves have the effects of reducing weight, improving hyperlipidemia and preventing myocardial infarction and cerebral hemorrhage. Alkaloids and polysaccharides are the main hypoglycemic components in mulberry leaves. The hypoglycemic effect of mulberry leaves is realized through two ways: the method has the advantages that 1-Deoxynojirimycin (DNJ) serving as alkaloid has an inhibitory effect on activity of disaccharide degrading enzymes, so that absorption of disaccharide by small intestine is inhibited, and high peak value of blood sugar after eating is reduced; secondly, cell secretion of insulin is promoted through mulberry leaf alkaloid (fagomine) and mulberry leaf polysaccharide, and the insulin can promote the utilization of sugar by cells, the synthesis of hepatic glycogen and the improvement of glycometabolism, so that the effect of reducing blood sugar is finally achieved.
Momordica grosvenori: the high sweet taste is mainly used for replacing a sweetener, and the momordica grosvenori has increasingly attracted attention in recent years due to the effects of scavenging free radicals, resisting oxidation, regulating blood sugar and regulating immunity. Researches find that the momordica grosvenori powder and the extract thereof have no influence on blood sugar and sugar tolerance of normal mice, but have obvious blood sugar reducing effect on alloxan diabetic mice, have prevention and treatment effect on abnormal rise of serum cholesterol and serum triacylglycerol in the diabetic mice, can improve the content of serum high-density lipoprotein cholesterol, enable the blood fat level of organisms to tend to be normal, and prevent lipid metabolism disorder caused by diabetes. The fructus Siraitiae Grosvenorii flavone can inhibit ADP-induced platelet aggregation in rat, significantly reduce cholesterol and triacylglycerol content in hypercholesterolemic mouse, increase high density lipoprotein cholesterol level, prolong blood coagulation time of mouse, and has certain pharmacological effects of promoting blood circulation and removing blood stasis such as anticoagulation. Mogroside has protective effect on liver injury and fatty liver, and can effectively reduce AST and ALT activity in blood serum, improve pathological change degree of liver tissue, reduce MDA content of liver tissue homogenate, and increase SOD activity.
Has the advantages that: compared with the prior art, the invention has the beneficial effects that: the invention adopts the mode of adding seasoning tea, so that patients can take tea for health care every day, the tea is convenient, the side effect of medicines is avoided, and the cost is low.
The specific implementation mode is as follows:
the following describes in detail specific embodiments of the present invention.
Detailed description of the preferred embodiment 1
A safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting the cardiovascular system comprises the following components in parts by weight:
600 parts of tea, 200 parts of safflower, 150 parts of perilla fruit, 150 parts of lotus plumule, 150 parts of cassia seed, 100 parts of medlar, 100 parts of chrysanthemum, 100 parts of sophora flower bud, 150 parts of hawthorn, 150 parts of mulberry leaf and 20 parts of momordica grosvenori.
Further, the tea leaves are oolong tea.
A preparation method of safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular comprises the following steps:
(1) preparing a first filtrate:
(11) weighing the safflower, the perilla fruit, the medlar, the chrysanthemum and the sophora flower bud according to the formula ratio, selecting, screening and removing impurities, cleaning, and placing in an extraction container;
(12) and leaching for the first time:
adding 15 times volume of 60% V/V ethanol water solution into the extraction container, leaching for 50 hours at 35 ℃, filtering, and collecting leaching liquor;
(13) and leaching for the second time:
adding 60% V/V ethanol water solution with volume 12 times of the extraction container, leaching at 55 deg.C for 36 hr, filtering, and collecting leaching solution;
(14) and leaching for the third time:
adding 40% V/V ethanol water solution with volume 12 times of the extraction container, leaching at 50 deg.C for 36 hr, filtering, and collecting leaching solution;
(15) combining the leaching liquor obtained in the steps (12) to (14), naturally cooling to normal temperature, standing in an environment of 5 ℃ for 48 hours, collecting supernatant, filtering by using a filter material with a pore size of 0.4 micron, and collecting filtrate to obtain first filtrate;
(2) preparing a second filtrate:
(21) weighing lotus plumule, cassia seed, hawthorn, mulberry leaf and momordica grosvenori according to the formula ratio, selecting, screening and cleaning impurities, and placing the mixture into an extraction container;
(22) and first decoction:
adding water with the volume 20 times that of the extraction container, soaking for 3 hours, heating to boil, decocting for 3 hours, filtering, and collecting decoction;
(23) and carrying out second decoction:
adding 10 times of water into the extraction container, heating to boil, decocting for 2 hours, filtering, and collecting decoction;
(24) and decocting for the third time:
adding 15 times of water into the extraction container, heating to boil, decocting for 3 hours, filtering, and collecting decoction;
(25) mixing the decoctions obtained in the steps (22) to (24), filtering by a 100-mesh filter screen, centrifuging by 600g to remove fine precipitates, concentrating the supernatant under reduced pressure at 70 ℃ and-0.07 MPa, and concentrating to obtain a concentrated solution with the relative density of 1.15 to obtain a second filtrate;
(3) adding 90% V/V ethanol water solution with the volume of 3 times of that of the second filtrate obtained in the step (2) into the second filtrate at 40 ℃, fully stirring the mixture, naturally cooling the mixture to the normal temperature, standing the mixture in an environment at 15 ℃ for 48 hours, collecting supernatant, filtering the supernatant by using a filter material with the filter diameter of 0.5 micron, and collecting filtrate;
(4) combining the first filtrate obtained in the step (1) and the filtrate obtained in the step (3), fully and uniformly mixing, concentrating under reduced pressure at 75 ℃ and-0.07 MPa, and concentrating the filtrate to the volume of a concentrated solution: the feeding amount of the raw materials is 1:2, and a concentrated solution is obtained, wherein:
the volume of the concentrated solution is measured by milliliter, and the feeding amount of the raw materials is measured by gram;
(5) weighing the picked tea leaves according to the formula ratio, flatly paving the tea leaves in a baking pan with the paving thickness of 4 cm, and placing the baking pan paved with the tea leaves in an oven for baking for 3 hours in a ventilation mode at the temperature of 80 ℃;
(6) uniformly spraying the concentrated solution obtained in the step (4) onto the tea leaves in the baking pan for 5 times, and fully stirring to enable the liquid medicine to be completely adsorbed by the tea leaves, wherein:
continuously baking the tea leaves at 65 ℃ for 6 hours in a ventilating way between two adjacent spraying processes, and uniformly turning over the materials every 2 hours;
(7) and (3) after the concentrated solution obtained in the step (4) is completely and uniformly mixed with the tea leaves in the tray, continuously carrying out ventilation baking at the temperature of 80 ℃, uniformly turning over the materials every 1 hour until the tea leaves are dry and have slight sense of thorny, gripping the tea leaves, enabling the tea leaves to have elasticity and be conglobate, and slightly forcibly touching the tea leaves to enable the tea leaves to be scattered, thus preparing the safflower Suxin tea for reducing hypertension, hyperglycemia and hyperlipidemia and protecting the cardiovascular system.
Further, the method also comprises the step (8): and (3) adding the safflower perilla heart tea prepared in the step (7) for reducing the three highs and protecting the cardiovascular system into an automatic packaging machine for packaging, and packaging the safflower perilla heart tea into 100 g of independent packages by aluminum-plastic packaging to obtain the safflower perilla heart tea which is independently packaged and used for reducing the three highs and protecting the cardiovascular system.
Further, ethanol is recovered simultaneously during the concentration under reduced pressure in the step (4).
Further, the tea leaves in the step (5) are oolong tea.
Specific example 2
A safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting the cardiovascular system comprises the following components in parts by weight: 15 parts of tea, 5 parts of safflower, 5 parts of perilla fruit, 5 parts of lotus plumule, 5 parts of cassia seed, 2 parts of medlar, 2 parts of chrysanthemum, 2 parts of sophora flower bud, 5 parts of hawthorn, 5 parts of mulberry leaf and 1 part of momordica grosvenori. Further, the tea leaves are green tea.
A preparation method of safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular comprises the following steps:
(1) preparing a first filtrate:
(11) weighing the safflower, the perilla fruit, the medlar, the chrysanthemum and the sophora flower bud according to the formula ratio, selecting, screening and removing impurities, cleaning, and placing in an extraction container;
(12) and leaching for the first time:
adding 10% V/V ethanol aqueous solution with volume 5 times of the extraction container, leaching for 96 hours at 20 ℃, filtering, and collecting the leaching liquor;
(13) and leaching for the second time:
adding 85% V/V ethanol water solution with volume 3 times of the extraction container, leaching for 72 hours at 20 ℃, filtering, and collecting leaching liquor;
(14) and leaching for the third time:
adding 10% V/V ethanol water solution with volume 3 times of the extraction container, leaching for 72 hours at 20 ℃, filtering, and collecting leaching liquor;
(15) combining the leaching liquor obtained in the steps (12) to (14), naturally cooling to normal temperature, standing in an environment at 1 ℃ for 96 hours, collecting supernatant, filtering by using a filter material with a pore size of 0.2 micron, and collecting filtrate to obtain first filtrate;
(2) preparing a second filtrate:
(21) weighing lotus plumule, cassia seed, hawthorn, mulberry leaf and momordica grosvenori according to the formula ratio, selecting, screening and cleaning impurities, and placing the mixture into an extraction container;
(22) and first decoction:
adding 8 times of water into the extraction container, soaking for 0.5 hr, heating to boil, decocting for 0.5 hr, filtering, and collecting decoction;
(23) and carrying out second decoction:
adding 6 times of water into the extraction container, heating to boil, decocting for 0.5 hr, filtering, and collecting decoction;
(24) and decocting for the third time:
adding 6 times of water into the extraction container, heating to boil, decocting for 0.5 hr, filtering, and collecting decoction;
(25) mixing the decoctions obtained in the steps (22) to (24), filtering by a 20-mesh filter screen, centrifuging by 300g to remove fine precipitates, concentrating the supernatant under reduced pressure at 55 ℃ and-0.1 MPa, and concentrating to obtain a concentrated solution with the relative density of 1.05, thereby obtaining a second filtrate;
(3) adding 90% V/V ethanol water solution with 2 times volume amount into the second filtrate obtained in the step (2) at the temperature of 5 ℃, fully stirring, naturally cooling to normal temperature, standing for 96 hours at the temperature of 1 ℃, collecting supernatant, filtering the supernatant by using a 0.2 micron filter material, and collecting filtrate;
(4) combining the first filtrate obtained in the step (1) and the filtrate obtained in the step (3), fully and uniformly mixing, concentrating under reduced pressure at 55 ℃ and-0.1 MPa, and concentrating the filtrate to the volume of a concentrated solution: the feeding amount of the raw materials is 1:1, and a concentrated solution is obtained, wherein:
the volume of the concentrated solution is measured by milliliter, and the feeding amount of the raw materials is measured by gram;
(5) weighing the picked tea leaves according to the formula ratio, flatly paving the tea leaves in a baking pan with the paving thickness of 0.5 cm, and placing the baking pan paved with the tea leaves in a baking oven for ventilation baking for 0.5 hour at 65 ℃;
(6) uniformly spraying the concentrated solution obtained in the step (4) onto the tea leaves in the baking pan for 1 time, and fully stirring to enable the concentrated solution to be completely adsorbed by the tea leaves;
(7) and (3) after the concentrated solution obtained in the step (4) is completely and uniformly mixed with the tea leaves in the tray, continuously carrying out ventilation baking at 65 ℃, uniformly turning over the materials every 0.5 hour until the tea leaves are dry and slightly pungent, gripping the tea leaves, enabling the tea leaves to be elastic and to be conglobated, and slightly forcibly touching the tea leaves to enable the tea leaves to be scattered, thus preparing the safflower Suxin tea for reducing hypertension, hyperglycemia and hyperlipidemia and protecting the cardiovascular system.
Further, the method also comprises the step (8): and (3) adding the safflower perilla heart tea prepared in the step (7) for reducing the three highs and protecting the cardiovascular system into an automatic packaging machine for packaging, and carrying out aluminum-plastic packaging to obtain 1 g of independent packages, namely the safflower perilla heart tea for reducing the three highs and protecting the cardiovascular system.
Further, ethanol is recovered simultaneously during the concentration under reduced pressure in the step (4).
Further, the tea leaves in the step (5) are green tea.
Specific example 3
A safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting the cardiovascular system comprises the following components in parts by weight: 1000 parts of tea, 300 parts of safflower, 100 parts of perilla fruit, 100 parts of lotus plumule, 300 parts of cassia seed, 300 parts of medlar, 300 parts of chrysanthemum, 150 parts of sophora flower bud, 300 parts of hawthorn, 300 parts of mulberry leaf and 50 parts of momordica grosvenori.
Further, the tea leaves are white tea.
A preparation method of safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular comprises the following steps:
(1) preparing a first filtrate:
(11) weighing the safflower, the perilla fruit, the medlar, the chrysanthemum and the sophora flower bud according to the formula ratio, selecting, screening and removing impurities, cleaning, and placing in an extraction container;
(12) and leaching for the first time:
adding 25 times volume of 85% V/V ethanol water solution into the extraction container, leaching at 75 deg.C for 4 hr, filtering, and collecting leaching solution;
(13) and leaching for the second time:
adding 10% V/V ethanol water solution with 20 times volume into the extraction container, leaching for 2 hours at 75 ℃, filtering, and collecting leaching liquor;
(14) and leaching for the third time:
adding 85% V/V ethanol water solution with 20 times volume into the extraction container, leaching at 75 deg.C for 2 hr, filtering, and collecting leaching solution;
(15) combining the leaching liquor obtained in the steps (12) to (14), naturally cooling to normal temperature, standing in a 10 ℃ environment for 12 hours, collecting supernatant, filtering by using a filter material with a pore size of 0.5 micron, and collecting filtrate to obtain first filtrate;
(2) preparing a second filtrate:
(21) weighing lotus plumule, cassia seed, hawthorn, mulberry leaf and momordica grosvenori according to the formula ratio, selecting, screening and cleaning impurities, and placing the mixture into an extraction container;
(22) and first decoction:
adding 30 times of water into the extraction container, soaking for 4.5 hours, heating to boil, decocting for 4.5 hours, filtering, and collecting decoction;
(23) and carrying out second decoction:
adding 25 times of water into the extraction container, heating to boil, decocting for 4.5 hours, filtering, and collecting decoction;
(24) and decocting for the third time:
adding 25 times of water into the extraction container, heating to boil, decocting for 4.5 hours, filtering, and collecting decoction;
(25) combining the decoction obtained in the steps (22) to (24), filtering the decoction by a 300-mesh filter screen, centrifuging 1200g of the filtrate to remove fine precipitates, concentrating the supernatant under reduced pressure at 95 ℃ and-0.05 MPa, and concentrating the concentrate to obtain a concentrated solution with the relative density of 1.25, thereby obtaining a second filtrate;
(3) adding 90% V/V ethanol water solution with 4 times volume amount into the second filtrate obtained in the step (2) at 65 ℃, fully stirring, naturally cooling to normal temperature, standing in an environment at 25 ℃ for 12 hours, collecting supernatant, filtering the supernatant by using a filter material with the filter diameter of 1.0 micron, and collecting filtrate;
(4) combining the first filtrate obtained in the step (1) and the filtrate obtained in the step (3), fully and uniformly mixing, concentrating under reduced pressure at 95 ℃ and-0.05 MPa, and concentrating the filtrate to the volume of a concentrated solution: the feeding amount of the raw materials is 1:4, and a concentrated solution is obtained, wherein:
the volume of the concentrated solution is measured by milliliter, and the feeding amount of the raw materials is measured by gram;
(5) weighing the picked tea leaves according to the formula ratio, flatly paving the tea leaves in a baking pan with the paving thickness of 8 cm, and placing the baking pan paved with the tea leaves in an oven for 4 hours at 120 ℃ for ventilation baking;
(6) uniformly spraying the concentrated solution obtained in the step (4) on the tea leaves in the baking pan for 10 times, and fully stirring to ensure that the liquid medicine is completely adsorbed by the tea leaves, wherein:
between two adjacent spraying, continuously baking the tea leaves for 2 hours at 120 ℃ in a ventilating way, and uniformly turning over the materials every 0.5 hour;
(7) and (3) after the concentrated solution obtained in the step (4) is completely and uniformly mixed with the tea leaves in the tray, continuously carrying out ventilation baking at the temperature of 120 ℃, uniformly turning over the materials every 0.5 hour until the tea leaves are dry and have slight sense of thorny, gripping the tea leaves, enabling the tea leaves to have elasticity, forming a cluster, and slightly forcibly touching the tea leaves to enable the tea leaves to be scattered, thus preparing the safflower Suxin tea for reducing hypertension, hyperglycemia and hyperlipidemia and protecting the cardiovascular system.
And (8) adding the safflower perilla heart tea prepared in the step (7) for reducing the three-high blood pressure and protecting the cardiovascular system into an automatic packaging machine for packaging, and packaging 5000 g of independent packages by aluminum-plastic packaging to obtain the safflower perilla heart tea which is independently packaged and used for reducing the three-high blood pressure and protecting the cardiovascular system.
Further, ethanol is recovered simultaneously during the concentration under reduced pressure in the step (4).
Further, the tea leaves in the step (5) are white tea.
Examples 4 to 7
The same as example 1, except that the tea leaves were selected:
Figure BDA0002686885580000221
Figure BDA0002686885580000231
the embodiments of the present invention have been described in detail. However, the present invention is not limited to the above-described embodiments, and various changes can be made within the knowledge of those skilled in the art without departing from the spirit of the present invention.

Claims (7)

1. The safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting the cardiovascular system is characterized by comprising the following components in parts by weight: 15-1000 parts of tea, 5-300 parts of safflower, 5-150 parts of perillaseed, 5-150 parts of lotus plumule, 5-300 parts of cassia seed, 2-300 parts of medlar, 2-300 parts of chrysanthemum, 2-150 parts of sophora flower bud, 5-300 parts of hawthorn, 5-300 parts of mulberry leaf and 1-50 parts of momordica grosvenori.
2. The safflower perilla heart tea for reducing high blood pressure, high blood sugar and protecting the cardiovascular system as claimed in claim 1, which comprises: 600 parts of tea, 200 parts of safflower, 150 parts of perilla fruit, 150 parts of lotus plumule, 150 parts of cassia seed, 100 parts of medlar, 100 parts of chrysanthemum, 100 parts of sophora flower bud, 150 parts of hawthorn, 150 parts of mulberry leaf and 20 parts of momordica grosvenori.
3. The safflower perilla heart tea for reducing high blood pressure, high blood sugar and protecting the cardiovascular system as claimed in claim 2, wherein the tea is any one or more of green tea, white tea, yellow tea, oolong tea, black tea and black tea.
4. A preparation method of the safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting the cardiovascular system of any one of claims 1 to 3 is characterized by comprising the following steps:
(1) preparing a first filtrate:
(11) weighing the safflower, the perilla fruit, the medlar, the chrysanthemum and the sophora flower bud according to the formula ratio, selecting, screening and removing impurities, cleaning, and placing in an extraction container;
(12) and leaching for the first time:
adding 10-85% V/V ethanol aqueous solution with the volume 5-25 times that of the extraction container, leaching for 4-96 hours at the temperature of 20-75 ℃, filtering, and collecting leaching liquor;
(13) and leaching for the second time:
adding 10-85% V/V ethanol aqueous solution with the volume of 3-20 times that of the extraction container, leaching for 2-72 hours at the temperature of 20-75 ℃, filtering, and collecting leaching liquor;
(14) and leaching for the third time:
adding 10-85% V/V ethanol aqueous solution with the volume of 3-20 times that of the extraction container, leaching for 2-72 hours at the temperature of 20-75 ℃, filtering, and collecting leaching liquor;
(15) combining the leaching liquor obtained in the steps (12) to (14), naturally cooling to normal temperature, standing for 12-96 hours in an environment at 1-10 ℃, collecting supernatant, filtering by using a filter material with a pore size of 0.2-0.5 micrometer, and collecting filtrate to obtain first filtrate;
(2) preparing a second filtrate:
(21) weighing lotus plumule, cassia seed, hawthorn, mulberry leaf and momordica grosvenori according to the formula ratio, selecting, screening and cleaning impurities, and placing the mixture into an extraction container;
(22) and first decoction:
adding 8-30 times of water into the extraction container, soaking for 0.5-4.5 hours, heating to boil, decocting for 0.5-4.5 hours, filtering, and collecting decoction;
(23) and carrying out second decoction:
adding 6-25 times of water by volume into the extraction container, heating to boil, decocting for 0.5-4.5 hours, filtering, and collecting decoction;
(24) and decocting for the third time:
adding 6-25 times of water by volume into the extraction container, heating to boil, decocting for 0.5-4.5 hours, filtering, and collecting decoction;
(25) combining the decoction obtained in the steps (22) to (24), filtering the decoction by a filter screen of 20-300 meshes, centrifuging 300-1200 g to remove fine precipitates, concentrating the supernatant under reduced pressure at 55-95 ℃ and-0.05-0.1 MPa, and concentrating the concentrate into a concentrated solution with the relative density of 1.05-1.25 to obtain a second filtrate;
(3) adding 2-4 times of volume of 90% V/V ethanol aqueous solution into the second filtrate obtained in the step (2) at the temperature of 5-65 ℃, fully stirring, naturally cooling to normal temperature, standing for 12-96 hours in an environment at the temperature of 1-25 ℃, collecting supernatant, filtering the supernatant through a filter material with the filter diameter of 0.2-1.0 micron, and collecting filtrate;
(4) combining the first filtrate obtained in the step (1) and the filtrate obtained in the step (3), fully and uniformly mixing, concentrating under reduced pressure at 55-95 ℃, and-0.05-0.1 MPa, and concentrating the filtrate to the volume of a concentrated solution: the feeding amount of the raw materials is 1 (1-4), and a concentrated solution is obtained, wherein:
the volume of the concentrated solution is measured by milliliter, and the feeding amount of the raw materials is measured by gram;
(5) weighing the picked tea leaves according to the formula ratio, flatly paving the tea leaves in a baking pan with the paving thickness of 0.5-8 cm, and placing the baking pan paved with the tea leaves in a baking oven for ventilation baking at 65-120 ℃ for 0.5-4 hours;
(6) uniformly spraying the concentrated solution obtained in the step (4) on the tea leaves in the baking pan for 1-10 times, and fully stirring to enable the liquid medicine to be completely adsorbed by the tea leaves, wherein:
between two adjacent spraying, continuously baking the tea leaves for 2-6 hours at 65-120 ℃ in a ventilating way, and uniformly turning over the materials every 0.5-2 hours;
(7) and (3) after the concentrated solution obtained in the step (4) is completely and uniformly mixed with the tea leaves in the tray, continuously performing ventilation baking at 65-120 ℃, uniformly turning over the materials every 0.5-2 hours until the tea leaves are dry and slightly pungent, gripping the tea leaves, enabling the tea leaves to be elastic and conglobate, and slightly touching the tea leaves with force to disperse tea leaves particles, thus preparing the safflower Suxin tea for reducing hypertension, hyperglycemia and hyperlipidemia and protecting the cardiovascular system.
5. The preparation method of the safflower perilla heart tea for reducing high blood pressure, high blood sugar and protecting the cardiovascular system according to claim 4, further comprising the step (8): and (3) adding the safflower perilla heart tea prepared in the step (7) for reducing the three highs and protecting the cardiovascular system into an automatic packaging machine for packaging, and carrying out aluminum-plastic packaging to obtain 1-5000 g of independent packages, thus obtaining the safflower perilla heart tea for reducing the three highs and protecting the cardiovascular system.
6. The method for preparing safflower perilla heart tea for reducing high blood pressure, high blood sugar and protecting cardiovascular as claimed in claim 4, wherein ethanol is recovered simultaneously during the process of vacuum concentration in step (4).
7. The method for preparing the safflower perilla heart tea for reducing high blood pressure, high blood sugar and protecting the cardiovascular system according to claim 4, wherein the tea leaves in the step (5) are any one or more of green tea, white tea, yellow tea, oolong tea, black tea and black tea.
CN202010979113.6A 2020-09-17 2020-09-17 Safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular and preparation method thereof Pending CN111919934A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010979113.6A CN111919934A (en) 2020-09-17 2020-09-17 Safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010979113.6A CN111919934A (en) 2020-09-17 2020-09-17 Safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular and preparation method thereof

Publications (1)

Publication Number Publication Date
CN111919934A true CN111919934A (en) 2020-11-13

Family

ID=73334552

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010979113.6A Pending CN111919934A (en) 2020-09-17 2020-09-17 Safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular and preparation method thereof

Country Status (1)

Country Link
CN (1) CN111919934A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112386545A (en) * 2020-12-18 2021-02-23 傅松涛 Baijin tea extract gargle and preparation method thereof
CN112471299A (en) * 2020-12-18 2021-03-12 傅松涛 Judai peach blossom tea with effects of relaxing bowel, reducing blood fat and losing weight and preparation method thereof
CN112841352A (en) * 2021-02-01 2021-05-28 青海大学 Lipid-lowering cornus macrophylla seed oil tea as well as preparation method and application thereof
CN115990211A (en) * 2023-02-15 2023-04-21 北京鹤之堂中医研究院有限公司 Traditional Chinese medicine probiotics composition for reducing blood pressure and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007006203A1 (en) * 2005-07-07 2007-01-18 Shirong Duan A capsule formulation for treating hypertension and coronary heart disease and process for preparation thereof
CN101401601A (en) * 2006-10-18 2009-04-08 吴建生 Five-leaf tea for reducing blood pressure, blood fat and blood sugar
WO2018053731A1 (en) * 2016-09-21 2018-03-29 刘嘉辉 Healthcare tea and preparation method therefor
CN108815474A (en) * 2018-09-07 2018-11-16 山东恒糅酒业有限公司 A kind of health-care Chinese medicinal composition and preparation method thereof with lower hyperlipidemia, hypertension, hyperglycemia
CN110150415A (en) * 2019-06-20 2019-08-23 珠海林尚熙养生茶业有限公司 A kind of three high tea-drinkings and preparation method thereof of tranquilizing the mind defaecation prevention

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007006203A1 (en) * 2005-07-07 2007-01-18 Shirong Duan A capsule formulation for treating hypertension and coronary heart disease and process for preparation thereof
CN101401601A (en) * 2006-10-18 2009-04-08 吴建生 Five-leaf tea for reducing blood pressure, blood fat and blood sugar
WO2018053731A1 (en) * 2016-09-21 2018-03-29 刘嘉辉 Healthcare tea and preparation method therefor
CN108815474A (en) * 2018-09-07 2018-11-16 山东恒糅酒业有限公司 A kind of health-care Chinese medicinal composition and preparation method thereof with lower hyperlipidemia, hypertension, hyperglycemia
CN110150415A (en) * 2019-06-20 2019-08-23 珠海林尚熙养生茶业有限公司 A kind of three high tea-drinkings and preparation method thereof of tranquilizing the mind defaecation prevention

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112386545A (en) * 2020-12-18 2021-02-23 傅松涛 Baijin tea extract gargle and preparation method thereof
CN112471299A (en) * 2020-12-18 2021-03-12 傅松涛 Judai peach blossom tea with effects of relaxing bowel, reducing blood fat and losing weight and preparation method thereof
CN112841352A (en) * 2021-02-01 2021-05-28 青海大学 Lipid-lowering cornus macrophylla seed oil tea as well as preparation method and application thereof
CN115990211A (en) * 2023-02-15 2023-04-21 北京鹤之堂中医研究院有限公司 Traditional Chinese medicine probiotics composition for reducing blood pressure and preparation method thereof

Similar Documents

Publication Publication Date Title
CN111919934A (en) Safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular and preparation method thereof
CN103041118B (en) Composition with effects of reducing blood sugar and reducing blood lipid
CN108404019A (en) Compound chicory root adjusts the solid articles and preparation method thereof of purine metabolic disturbance
CN101518595A (en) Medical composition with functions of lowering lipid, reducing fat and oxidation resistance and preparation method thereof
CN108524673A (en) A kind of Chinese medicine composition and its application
CN105250913B (en) A kind of pharmaceutical composition for treating laying hen fatty liver syndrome
CN101084984A (en) Porridge with intestines-moistening and eyesight-improving function
JP4516958B2 (en) Anti-diabetic composition
CN107494817A (en) A kind of hypoglycemic tea
CN102178008A (en) Health-care nourishing tea capable of relieving blood pressure, blood fat and blood sugar
CN110538311A (en) Pure traditional Chinese medicine composition for controlling hypertension and preparation method thereof
CN110251591A (en) A kind of pharmaceutical composition and its preparation method and application that aided blood pressure-lowering is hypoglycemic
CN102125632A (en) Chinese medicinal healthy tea for preventing and treating hypertension
CN108077485A (en) A kind of blue or green money willow herbal tea and preparation method thereof
CN107712890A (en) A kind of antitoxic heart-soothing and sedative cream taste and preparation method thereof
KR20180079920A (en) Composition for preventing, improving or treating hepatic fibrosis or liver cirrhosis comprising Cuscuta Semen extract
CN109549206A (en) A kind of thrombolysis and the functional food and preparation method thereof for preventing cardiovascular disease
CN112970992A (en) Solid beverage suitable for diabetes patients and preparation method thereof
CN103652059B (en) The formula of bagged medicine tea and preparation method
CN106692760A (en) Golden flower wine formula for preventing diabetes and preparation method thereof
CN111905087A (en) Health-care product composition for dispelling effects of alcohol and protecting liver
CN105311375A (en) Composition for reducing blood lipid
KR100496622B1 (en) Alcohol fermented food or pharmaceutical composition for prevention of obesity and process for preparation thereof
CN111955570A (en) Ginseng white ganoderma lucidum tea capable of enhancing immunity and preventing tumors and production process thereof
CN101278940A (en) Medicament composition for curing diabetic cardiovascular pathological changes and method of preparing the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20201113

RJ01 Rejection of invention patent application after publication